RAPID-MEDICAL
25.5.2021 16:05:13 CEST | Business Wire | Press release
Rapid Medical, a company focused on the development of responsive, adjustable neurovascular devices, announced today that it has completed an oversubscribed Series D financing of $50M. The proceeds will be used to support the fast commercial growth of the company’s minimally invasive stroke products worldwide. The round was led by MicroPort with participation from CITIC private equity fund (CPE), Deep Insight and existing investors.
Rapid Medical recently announced the FDA clearance of its TIGERTRIEVER™ revascularization device for use in the treatment of ischemic stroke. TIGERTRIEVER is a new class of clot retriever. The device’s intelligent control enables neuro interventionalists to better remove blood clots and restore blood flow to the brain following an ischemic event—a condition that devastates 700,000 Americans annually. TIGERTRIEVER 13, the smallest device in the TIGERTRIEVER portfolio, is the only clot retriever in the world indicated for the removal clots from more distant areas in the brain. TIGERTRIEVER 13 is CE marked and not cleared by the FDA.
The proceeds will be used to expand commercial operations in US and Europe, create additional clinical evidence supporting the superiority of the company’s products, and advance the product development pipeline utilizing company’s proprietary braiding technology platform. In addition, the funding will be used to obtain regulatory approvals in new strategic territories such as China.
“We’ve revolutionized intravascular devices by providing physicians with the ability to remotely adjust devices to the anatomy. We are thrilled that this new round will allow us to expand this mission,” said Ronen Eckhouse, co-founder and CEO of Rapid Medical. “We are excited about the quality of new and existing investors joining this financing.”
As part of the financing round, Chen Chen, a principle at CPE, will join Rapid Medical’s board of directors.
Jefferies LLC served as exclusive placement agent for Rapid Medical in the financing.
About Rapid Medical
Rapid Medical develops the premier responsive interventional devices for endovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER ™ 17 and 21, COMANECI ™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER ™ 13 and XL are also CE marked. More information is available at www.rapid-medical.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005608/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 09:00:00 CEST | Press release
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evot
Freedom Holding Corp. Works With Ant International’s Antom to Simplify Online Shopping From China for Kazakhstan Consumers23.7.2026 07:30:00 CEST | Press release
Freedom Bank SuperApp to be promoted as a payment option on China’s leading e-commerce platforms through Antom On July 16, 2026, during a meeting between Timur Turlov, CEO of Freedom Holding Corp., and representatives of the global fintech market, the bank signed Memoranda of Understanding with Antom, a leading merchant payment and digitisation services provider under Ant International. The primary goal of this partnership is to develop innovative solutions to facilitate cross-border payments for consumers in Kazakhstan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722367119/en/ From left to right: Timur Turlov, CEO of Freedom Holding Corp., Leiming Chen, Senior Vice President and Chief Sustainability Officer of Ant International Antom will promote Freedom Bank SuperApp as a supported payment option on China’s leading e-commerce platforms. This move aims to create a seamless cross-border online shopping experience, allo
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year23.7.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix. Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology. Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ra
ATOZ Services Announces Strategic Growth Investment from Bregal Sagemount23.7.2026 06:30:00 CEST | Press release
Investment will support geographic expansion, AI investment and continued growth across ATOZ Services’ fund services platform ATOZ Services (The “Company”), an independent Luxembourg-based fund services platform, today announced that the Company will accelerate its strategic move to continue its international expansion and acquisition-based strategy through a growth investment from Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm. Sagemount has entered into a partnership with ATOZ Group and ICG that will see Sagemount become the majority shareholder of the Company, while ATOZ Group and ICG retain a minority stake, subject to regulatory approval and other customary procedures. The investment will support the Company’s continued development as an international fund services platform. Founded in 2018 as part of the ATOZ Group, ATOZ Services provides fund-linked special purpose vehicle (“SPV”) services, fund administration, and fund governance, risk and complian
Airship Announces Results Guarantee; Releases Commissioned Study Finding 476% ROI for Composite Organization22.7.2026 17:00:00 CEST | Press release
Airship stands behind results with new guarantee offer*; also launches a commissioned study quantifying how a composite organization moved past vanity metrics to drive $7.3M in value Airship, the mobile-first customer experience platform leader, today announced its Airship Results Guarantee, a corporate commitment to achieve predetermined business outcomes for new customers. Concurrently, the company released the results of a separate, commissioned Total Economic Impact™ (TEI) study conducted by Forrester Consulting on behalf of Airship, July 2026. The study found that a composite organization based on interviewed customers achieved a 476% Return on Investment (ROI) with a payback period of less than six months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722832535/en/ Airship has launched a new results guarantee offer to stand behind its value. Alongside this offer, the team shared the results of a new Total Economic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom